Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes

NCT01140893 on ClinicalTrials.gov · last registry update 2016-08-23

110 participants. Its estimated completion date, May 2017, has passed with no update to the record. Primary outcome, as filed: Change from baseline to 6 months of centrally measured HbA1c. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P2/P3
Drug: exenatide
Bydureon, Byetta
Sponsor: University Hospital, Caen
Sponsor type: Other
Enrollment: 110
Started: 2010-11
Primary completion: 2017-05 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change from baseline to 6 months of centrally measured HbA1c

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.